Insider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 15,000 Shares of Stock

Sangamo Therapeutics Inc (NASDAQ:SGMO) VP Curt A. Herberts III sold 15,000 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $20.59, for a total value of $308,850.00. Following the sale, the vice president now owns 29,625 shares of the company’s stock, valued at approximately $609,978.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Curt A. Herberts III also recently made the following trade(s):

  • On Friday, December 1st, Curt A. Herberts III sold 16,630 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $16.13, for a total value of $268,241.90.

Sangamo Therapeutics Inc (NASDAQ:SGMO) opened at $22.10 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.64 and a quick ratio of 5.64. Sangamo Therapeutics Inc has a 1-year low of $3.55 and a 1-year high of $22.53.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.04. The business had revenue of $11.81 million during the quarter, compared to analysts’ expectations of $10.37 million. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The firm’s revenue for the quarter was up 333.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.27) EPS. analysts anticipate that Sangamo Therapeutics Inc will post -0.73 earnings per share for the current fiscal year.

Several analysts recently issued reports on SGMO shares. Piper Jaffray Companies set a $25.00 target price on Sangamo Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. BidaskClub upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. Zacks Investment Research upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research report on Wednesday, November 15th. Jefferies Group reiterated a “buy” rating and set a $18.00 target price on shares of Sangamo Therapeutics in a research report on Friday, October 13th. Finally, Wedbush restated a “hold” rating and set a $6.00 price target on shares of Sangamo Therapeutics in a report on Wednesday, November 15th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Sangamo Therapeutics presently has a consensus rating of “Buy” and an average target price of $18.83.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SGMO. Principal Financial Group Inc. grew its holdings in Sangamo Therapeutics by 6.8% during the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 832 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Sangamo Therapeutics in the 3rd quarter valued at approximately $118,000. Virtu KCG Holdings LLC bought a new stake in shares of Sangamo Therapeutics in the 2nd quarter valued at approximately $124,000. Amalgamated Bank bought a new stake in shares of Sangamo Therapeutics in the 3rd quarter valued at approximately $158,000. Finally, Great West Life Assurance Co. Can lifted its stake in shares of Sangamo Therapeutics by 150.3% in the 3rd quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 7,667 shares during the last quarter. Institutional investors and hedge funds own 64.06% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Sangamo Therapeutics Inc (SGMO) VP Sells 15,000 Shares of Stock” was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.com-unik.info/2018/02/08/insider-selling-sangamo-therapeutics-inc-sgmo-vp-sells-15000-shares-of-stock.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit